STUDY PROTOCOL

Impact of interventions including vaccination against *Neisseria meningitidis* on the frequency of meningitis in the African meningitis belt: a scoping review protocol [version 1; peer review: 2 approved]

Niurka Molina¹, Greissi Justiniani², Lisset Urquiza², Maria Eugenia Toledo¹, Chukwuemeka Onwuchekwa³, Kristien Verdonck³, Ermias Diro⁴, Nivaldo Linares-Pérez²

¹Instituto de Medicina Tropical Pedro Kourí, Havana, Cuba
²Instituto Finlay de Vacunas, Havana, Cuba
³Institute of Tropical Medicine, Antwerp, Belgium
⁴University of Gondar, Gondar, Ethiopia

First published: 15 Nov 2019, 8:1922
https://doi.org/10.12688/f1000research.21164.1

Open Peer Review

Approval Status

|   | 1 | 2 |
|---|---|---|
| version 1 | ✓ | ✓ |

15 Nov 2019

1. Clare French, University of Bristol, Bristol, UK
2. James M. Stuart, University of Bristol, Bristol, UK
3. Charlene M Kahler, University of Western Australia, Crawley, Australia

Any reports and responses or comments on the article can be found at the end of the article.

Abstract

In the African meningitis belt (region from Senegal to Ethiopia), there are around 30,000 reported cases of meningococcal disease per year. The main aetiological agent is *Neisseria meningitidis* of serogroup A. Since 2010, vaccination efforts have increased and hundreds of millions of people have been vaccinated. There are indications that the epidemiology of meningococcal disease is changing. This is the protocol of a scoping review, the objective of which is to describe the extent and nature of the research evidence about the impact of vaccination on meningitis frequency. Primary studies and reviews are eligible for inclusion in the review if they assess the impact of interventions that include *N. meningitidis* vaccination in countries of the African meningitis belt, report meningitis frequencies, and include an element of comparison. The sources of records are electronic databases (MEDLINE, Cochrane register of clinical trials, African Index Medicus, and clinicaltrials.gov), surveillance reports at country level, online resources of large stakeholders involved in vaccination, reference lists of included records, and experts in the field. The search strategy is based on the combination of the condition of interest, the intervention, and the geographical region. The findings of this review will be presented using figures, tables, and thematic narrative synthesis. This review will not produce a pooled estimate of what the impact of vaccination is, but will give insight in how the authors of the included records assessed the impact.
Corresponding author: Kristien Verdonck (tverdonck@itg.be)

Author roles: Molina N: Investigation, Project Administration, Writing – Original Draft Preparation; Justiniani G: Investigation, Writing – Original Draft Preparation; Urquiza L: Investigation, Writing – Original Draft Preparation; Toledo ME: Project Administration, Validation, Writing – Review & Editing; Onwuchekwa C: Methodology, Validation, Writing – Review & Editing; Verdonck K: Methodology, Resources, Supervision, Writing – Original Draft Preparation; Diro E: Methodology, Supervision, Validation, Writing – Review & Editing; Linares-Pérez N: Conceptualization, Supervision, Validation, Writing – Review & Editing

Competing interests: Three members of the review team work for the Finlay institute in Cuba, a centre for vaccine research and production. The topic of the review was proposed by staff of the Finlay Institute. Sponsors and institutes played no other role in the development and content of the protocol or the decision to submit.

Grant information: The review protocol was developed during a workshop on evidence synthesis in September 2019 in Cuba. The workshop was organised by the Instituto Pedro Kourí (Cuba), the Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia (Peru), and the Institute of Tropical Medicine of Antwerp (Belgium), and received partial support from the Belgian Development Cooperation through the Fourth Framework Agreement (FA4). The authors declared that no other grants were involved in supporting this work.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Molina N et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Molina N, Justiniani G, Urquiza L et al. Impact of interventions including vaccination against Neisseria meningitidis on the frequency of meningitis in the African meningitis belt: a scoping review protocol [version 1; peer review: 2 approved] F1000Research 2019, 8:1922 https://doi.org/10.12688/f1000research.21164.1

First published: 15 Nov 2019, 8:1922 https://doi.org/10.12688/f1000research.21164.1

Keywords
Neisseria meningitidis, vaccination, health impact assessment, scoping review
Introduction

*Neisseria meningitidis* is a Gram-negative bacterium that is found in the mucous membrane of the nasopharynx and tonsils of about 10% of the human population. Most *N. meningitidis* strains are harmless, but some encapsulated clones are virulent and can cause meningococcaemia, meningitis, and septic shock. Historically, the highest incidence of meningococcal disease has been described in sub-Saharan Africa, in the so-called African meningitis belt, which stretches from the west of Senegal to the east of Ethiopia. In this region, endemic rates are high, and large-scale epidemics have occurred every 8–12 years for more than a century, typically in dry seasons. The number of cases of meningococcal meningitis reported from the African meningitis belt is around 30,000 per year.

There are at least 13 serogroups of *N. meningitidis* (A, B, C, D, E, H, I, K, L, W135, X, Y, and Z) that are classified based on differences in capsule polysaccharides. Serogroup A used to be the main causative agent of epidemics in Africa, but massive vaccination campaigns are changing the epidemiology. Validated and licensed conjugate vaccines are available for serogroups A (MenAfriVac) and C, and there is also a tetravalent vaccine for serogroups A, C, Y, and W135. These vaccines can be used in routine settings (part of routine immunisation scheme) and in response to outbreaks (reactive vaccination). Vaccination efforts intensified in 2010 and since then, hundreds of millions of Africans have received a dose of MenAfriVac. As a consequence, the incidence of meningococcal meningitis due to serogroup A has decreased, but outbreaks of new clones have been reported.

Our main objective is to evaluate the impact of vaccination on morbidity and mortality due to meningococcal disease in countries of the African meningitis belt. Before engaging in a systematic review, we will assess the size and scope of the body of literature. The aim at this stage is not to produce a pooled estimate of what the impact of vaccination is, but to evaluate how the authors of the included records have assessed the impact.

Objectives

The central question of this scoping review is: what is the extent and the nature of the research evidence about the impact of interventions including vaccination against *Neisseria meningitidis* on the frequency of meningitis in the African meningitis belt? The review question is formulated using the SPICE (setting, perspective, intervention, comparison, evaluation) framework and the key elements are summarised in Table 1.

| Key element | Elaboration |
|-------------|-------------|
| Setting     | African meningitis belt where efforts to reduce the burden of meningitis due to *N. meningitidis* through vaccination have increased since 2010. |
| Perspective | Residents in the region who may benefit from vaccination. |
| Intervention| Interventions at individual or group level including *N. meningitidis* vaccination, combined or not with chemoprophylaxis for contacts, health information/education, other vaccines, etc. |
| Comparison  | Subgroups with and without intervention, populations before and after intervention. |
| Evaluation  | Impact in terms of a reduction in the frequency of meningitis or in the proportion of meningitis due to *N. meningitidis*. |
criteria will be pilot-tested on 50 titles and abstracts and refined if necessary.

**Information sources**

We will search the following electronic databases: MEDLINE, the Cochrane register of clinical trials, African Index Medicus, and clinicaltrials.gov. Other sources of information will be surveillance reports at country level and online resources of the World Health Organization and other large stakeholders involved in vaccination campaigns (to be identified via the included records). Finally, we also intend to screen the reference lists of included records (especially review papers) and contact experts in the field to check if we have missed any potentially relevant records. There will be no restrictions regarding language, publication date, or study design.

**Search strategy**

The search strategy is based on the combination of three concepts: the condition of interest, the intervention, and the geographical region (Figure 1). The Boolean operators “AND” and “OR” are used to combine search terms. The planned search syntax for PubMed is given in Table 2. The same general strategy will be used to search the other databases, but small adjustments will be made such as the translation of key words to French, and the adaptation of truncation symbols and parentheses to different search engines.

**Study records**

**Data management.** Retrieved records will be automatically exported to Microsoft Excel if possible (e.g. from PubMed) and manually added otherwise. All records will get a unique identifier. Information extracted from the included records will be stored in the Excel file. Records that remain after title and abstract screening will also be kept in an EndNote file.

**Selection process.** Record screening and selection will be done in duplicate by two independent members of the review team (LU and/or GJ and/or NM). Any discordsances during screening of titles and abstracts or full-text papers will be solved through discussion with a third member of the review team (KV). For each full-text record that we exclude, the main reason for exclusion will be recorded. The search and selection process will be documented in a PRISMA flowchart.

**Data collection process.** Two members of the review team (LU and/or GJ and/or NM) will independently extract the information from the included records using a standard form (preliminary version available as extended data). This data extraction form will be piloted on at least three full-text records and refined if necessary. The extracted information will first be filled out on the data extraction form (one form per reviewer and per record) and then passed to the Excel file. In case the information is unclear or incomplete, we will describe it as such; we do not intend to contact investigators. Any discordsances between the two reviewers will be discussed with a third reviewer (KV).

**Data items**

We will collect information about the record itself and about the study described in the record. Table 3 gives an overview of the data items. The complete preliminary data extraction form is available as extended data.

---

**Table 2. Planned search syntax for PubMed.**

| Search terms                                                                 |
|------------------------------------------------------------------------------|
| (neisseria meningitidis[Mesh]) OR ((Neisseria) AND meningit*) OR (meningoc*) |
| AND                                                                          |
| (Vaccination [Mesh]) OR (Vaccines [Mesh]) OR (Vaccinati*) OR (Vaccine*) OR (Immuni*) |
| AND                                                                          |
| “Benin” [Mesh] OR “Burkina Faso” [Mesh] OR “Burundi” [Mesh] OR “Cote d’Ivoire” [Mesh] OR “Cameroon” [Mesh] OR “Central African Republic” [Mesh] OR “Chad” [Mesh] OR “Democratic Republic of the Congo” [Mesh] OR “Eritrea” [Mesh] OR “Ethiopia” [Mesh] OR “Gambia” [Mesh] OR “Ghana” [Mesh] OR “Guinea” [Mesh] OR “Guinea-Bissau” [Mesh] OR “Kenya” [Mesh] OR “Mali” [Mesh] OR “Mauritania” [Mesh] OR “Niger” [Mesh] OR “Nigeria” [Mesh] OR “Rwanda” [Mesh] OR “Senegal” [Mesh] OR “South Sudan” [Mesh] OR “Sudan” [Mesh] OR “Tanzania” [Mesh] OR “Togo” [Mesh] OR “Uganda” [Mesh] OR “Benin” [All fields] OR “Burkina Faso” [All fields] OR “Burundi” [All fields] OR “Cote d’Ivoire” [All fields] OR “Cameroon” [All fields] OR “Central African Republic” [All fields] OR “Chad” [All fields] OR “Democratic Republic of the Congo” [All fields] OR “Eritrea” [All fields] OR “Ethiopia” [All fields] OR “Gambia” [All fields] OR “Ghana” [All fields] OR “Guinea” [All fields] OR “Guinea-Bissau” [All fields] OR “Kenya” [All fields] OR “Mali” [All fields] OR “Mauritania” [All fields] OR “Niger” [All fields] OR “Nigeria” [All fields] OR “Rwanda” [All fields] OR “Senegal” [All fields] OR “South Sudan” [All fields] OR “Sudan” [All fields] OR “Tanzania” [All fields] OR “Togo” [All fields] OR “Uganda” [All fields] OR “Congo” [All fields] OR “Zaire” [All fields] OR “Guinea Bissau” [All fields] OR “Côte d’Ivoire” [All fields]
Outcomes and prioritization
Rather than focusing on one or a few specific outcomes, this review focuses on the size and scope of the available research literature and on the nature and extent of the research evidence. The approach will be descriptive; we do not foresee outcome prioritization.

Risk of bias in individual studies
The assessment of risk of bias will be done at study level and independently by two people of our review team. As we are using broad eligibility criteria for this scoping review, we expect to include information in heterogeneous formats and coming from studies following different designs. For randomised trials of interventions, we plan to use the risk-of-bias assessment tool of the Cochrane Collaboration, and for non-randomised studies the ROBINS-I tool. For studies following other designs, we will only describe the study design and the ways impact of vaccination was described and assessed. We plan to describe and discuss the findings of the assessment of risk of bias and will not use them in any other way in data synthesis.

Data synthesis
The findings of this review will be presented using figures, tables, and thematic narrative synthesis. Data from the included studies will not be pooled and the synthesis will not lead to recommendations on vaccination for *N. meningitidis*.

A preliminary structure of the results section is given below, but this may slightly change depending on the content of the included papers:
- Search and selection (with PRISMA flowchart)
- Characteristics of included records: publication type, year, journal, author affiliations
- Study populations: country, setting, size, general population or subgroups
- Interventions: vaccination alone or in combination, rationale, in outbreak, routine or research settings, by government or others
- Vaccines used: type, brand, provider
- Approaches to assess impact: overview of definitions and operationalisation of impact
- Study design: according to the study authors and according to the review team
- Risk of bias assessment

Reporting and registration
The present review protocol was developed following the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) guidelines, more specifically the checklist for review protocols (PRISMA-P 2015) and the extension for scoping reviews (PRISMA-ScR 2018)\(^9\)\(^10\)\(^11\).

The review protocol will be published so that it is publicly available before the actual reviewing activities start. PROSPERO is a specialized platform for review protocols but does not accept scoping reviews. We therefore publish the current protocol on F1000Research, an open access scientific publishing platform. Any changes in the reviewing activities after protocol registration will be listed in the final review paper.

Planning
- Protocol publication: November 2019
- Search, selection, data extraction and synthesis: November 2019 – February 2020
- Writing of review paper: February 2020 – April 2020

Review team and roles
The review team is presented in Table 4.

Study status
While preparing the present protocol, we tried out preliminary searches to get an idea of the size of the available literature.
At the time of submission, formal reviewing activities had not started yet.

**Data availability**

**Underlying data**

No underlying data are associated with this study.

### References

1. Brandtzaeg P: *Oxford textbook of medicine: infection.* 5th ed. Oxford (United Kingdom): Oxford University Press; Chapter 6.5, Meningococcal infections; 2012; 318–332.
   **Reference Source**
2. Mustapha MM, Harrison LH: Vaccine prevention of meningococcal disease in Africa: major advances, remaining challenges. *Hum Vaccin Immunother.* 2018; 14(6): 1107–1115.
   **Published Abstract** | **Publisher Full Text** | **Free Full Text**
3. Mohammed I, Bayou G, Habib AG: Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa. *Pathog Glob Health.* 2017; 111(1): 1–6.
   **Published Abstract** | **Publisher Full Text** | **Free Full Text**
4. World Health Organization: Meningococcal meningitis key facts. (accessed 24 October 2019).
   **Reference Source**
5. Borrow R, Caugant DA, Ceyhan M, et al.: Meningococcal disease in the Middle East and Africa: Findings and updates from the Global Meningococcal Initiative. *J Infect.* 2017; 75(1): 1–11.
   **Published Abstract** | **Publisher Full Text**
6. Grant MJ, Booth A: A typology of reviews: an analysis of 14 review types and associated methodologies. *Health Info Libr J.* 2009; 26(2): 91–108.
   **PubMed Abstract** | **Publisher Full Text**
7. Booth A: Clear and present questions: Formulating questions for evidence based practice. *Library Hi Tech.* 2006; 24(3): 355–368.
   **Publisher Full Text**
8. Verdonck K: SupplementaryInformation_Eligibility_DataExtraction. *figshare.* Online resource. 2019.
   **http://www.doi.org/10.6084/m9.figshare.10078928.v1**
9. Liberati A, Altman DG, Tetzlaff J, et al.: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med.* 2009; 6(7): e1000100.
   **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**
10. Shamseer L, Moher D, Clarke M, et al.: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ.* 2015; 350: g7647.
   **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**
11. Tricco AC, Lillie E, Zarin W, et al.: PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* 2018; 169(7): 467–473.
   **PubMed Abstract** | **Publisher Full Text**

**Extended data**

*Figshare:* SupplementaryInformation_Eligibility_DataExtraction. https://doi.org/10.6084/m9.figshare.10078928.v1*

Data are available under the terms of the **Creative Commons Attribution 4.0 International license (CC-BY 4.0).**
**General comments**
The scoping review is well written and should achieve the outcomes stated.

**Minor comments**
Serogroup B disease is an issue in Africa and is increasing in frequency by causing local sporadic clusters, so this should be added to your search terms. Meningococcal disease is only one of many agents causing meningitis, so please be sure that your search terms can make this distinction or try to find studies that use follow up steps to confirm the causative agent. All cases of meningitis are treated the same - with ceftriaxone or penicillin, so you cannot really dissect useful information using this as a term to extract this information.

Overall, I look forward to the final outcome of this study as a review on this topic has not been done for some time.

**Is the rationale for, and objectives of, the study clearly described?**
Yes

**Is the study design appropriate for the research question?**
Yes

**Are sufficient details of the methods provided to allow replication by others?**
Yes

**Are the datasets clearly presented in a useable and accessible format?**
Yes

**Competing Interests:** No competing interests were disclosed.
Reviewer Expertise: Meningococcal disease, meningococcal genomic epidemiology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 03 June 2020

https://doi.org/10.5256/f1000research.23296.r63667

© 2020 Stuart J et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Clare French
Population Heath Sciences, Bristol Medical School, University of Bristol, Bristol, UK

James M. Stuart
Population Heath Sciences, Bristol Medical School, University of Bristol, Bristol, UK

General comments
This is a clearly written protocol for a scoping review to describe the extent and nature of the research evidence about the impact of vaccination on meningitis frequency. We note that this is being conducted before the research team embark on a full systematic review on the topic.

Introduction
Importantly the numbers of cases (30,000 a year) quoted refer to suspected cases due to any cause, not specifically meningococcal meningitis. I note that the WHO reference to key facts is misleading on this point. Most reported cases are not laboratory confirmed. The majority of confirmed cases are meningococcal, but a substantial proportion are pneumococcal meningitis.1

The authors should emphasize this in the protocol and clarify how they will take account of information on laboratory confirmation of meningococcal and other pathogens when interpreting the data obtained. This is clearly important in assessing the impact of meningococcal vaccines and the validity of the review.

Minor:
There are currently 12 (not 13) serogroups, and W135 is no longer used, it has been replaced by W2.

In the abstract, not in the main text, it is stated that Serogroup A is the main aetiological agent of meningitis in the belt. This was true until 2010, but not since.

There are 26 (not 27) countries in the meningitis belt according to WHO https://www.who.int/gho/epidemic_diseases/meningitis/en/.

1. Trotter, C.L., et al., *Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data.* Lancet Infect Dis, 2017. 17(8): p. 867-872.1

2. Harrison, O.B., et al., *Description and nomenclature of Neisseria meningitidis capsule locus.* Emerg Infect Dis, 2013. # 19(4): p. 566-73.2

Methods
The authors plan to search various sources in addition to electronic databases but they don’t mention searching conference abstracts. Though this is not essential for a scoping review it could be another way of identifying work in progress – such work may well have been published by the time the authors conduct their planned systematic review on the topic so it might be helpful to include it at this stage.

The search strategy looks fine for the purpose of a scoping review. The authors might consider adding the following Mesh term: ‘Meningococcal Infections’.
The authors state that they will include both primary studies and review articles. Some clarification is required as to how they will avoid reporting on individual studies more than once (i.e. where an eligible individual study is identified and that study is also included in an eligible systematic review) - will reviews be used as a means of identifying individual studies to report on or will they be reported on at the review level?

It sounds as though the search hits will be screened for eligibility in Excel. This is fine if it is the authors’ preference but an alternative could be to use free screening software such as Rayyan which can help organise and speed up the screening process (https://rayyan.qcri.org/welcome).

The authors state that they will assess the risk of bias for individual studies included in their review. Although this will be an important element of the full systematic review planned by the authors it is not necessarily required for a scoping review e.g. see the PRISMA extension for scoping reviews guidance on this: https://www.acpjournals.org/doi/10.7326/M18-0850. It is not clear that an assessment of risk of bias is required here. We suggest the authors give careful consideration as to whether this step is necessary, particularly given that it can be quite time consuming, and what it will add to the scoping review. If the authors do feel that risk of bias assessment is required, they should provide clear reasoning for this in relation to the review objectives.

References
1. Trotter C, Lingani C, Fernandez K, Cooper L, et al.: Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data. The Lancet Infectious Diseases. 2017; 17 (8): 867-872 Publisher Full Text
2. Harrison OB, Claus H, Jiang Y, Bennett JS, et al.: Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013; 19 (4): 566-73 PubMed Abstract | Publisher Full Text

Is the rationale for, and objectives of, the study clearly described?
Yes

Is the study design appropriate for the research question?
Yes

Are sufficient details of the methods provided to allow replication by others?
Yes

Are the datasets clearly presented in a useable and accessible format?
Not applicable
**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Epidemiology, meningococcal disease, research synthesis

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com